Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ESSA Pharma Inc EPIX

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).


NDAQ:EPIX - Post by User

Bullboard Posts
Post by lovincoalon Mar 21, 2017 10:00pm
247 Views
Post# 26011575

price should be double ($8) where it is now if good results

price should be double ($8) where it is now if good resultsif they release good results from their current trial, this should trade at a multiple of where it is now compared to other biotech companies in the US and it does trade on Nasdaq under EPIX. I think institutional investors are waiting (and rightly so) till the results are released before putting to their portfolio. That's when its true value will be recognized. Trading above $5 also means more institutions will be able to purchase it. I wouldn't be in a rush to sell IF the results are good as institutions will need a few days to review the results and start their buying.
I'll be adding to my position IF the results are good knowing that once institutions start buying it will take them several days to accumulate their position.
Good luck and let's hope for great results - it has been a long wait but hopefully worth it!
Bullboard Posts